Targeting Cancer Stem-Like Cells as an Approach to Defeating Cellular Heterogeneity in Ewing’s Sarcoma
Researchers assessed the effect of combining a drug that abrogates cancer stem-like cell (CSC) properties with standard-of-care therapy in a Ewing sarcoma family tumor (ESFT). Primary ESFT from four patients containing CD133+ CSC subpopulations ranging from 3-17% of total tumor cells were subjected to treatment with enoxacin, doxorubicin or both drugs. [Cancer Res] Abstract
Annexin A3 as a Potential Target for Immunotherapy of Liver Cancer Stem-Like Cells
Overexpression of Annexin A3 (ANXA3) increased the proportion of CD133+ cells, enhancing their tumorigenicity. On the contrary, knockdown of ANXA3 decreased CD133+ cells and inhibited tumorigenicity. The mechanistic study revealed that ANXA3-mediated maintenance of hepatocellular carcinoma cancer stem-like cell/cancer initiating cell activity was likely involved with the HIF1A/Notch pathway. [Stem Cells] Abstract
$7 Million Clinical Research Grant a Big Win for All New Mexicans
The University of New Mexico Cancer Center won a five-year $7 million grant from the National Cancer Institute’s National Community Oncology Research Program (NCORP). The NCORP grant will strengthen and expand the clinical trials network in New Mexico. [University of New Mexico Cancer Center] Press Release
Montefiore and Einstein Receive $3.4 Million NIH Grant for Cancer Clinical Trials
Montefiore Einstein Center for Cancer Care and Albert Einstein College of Medicine of Yeshiva University have been awarded a $3.4 million grant from the National Cancer Institute to conduct multi-site cancer clinical trials and research focused on reducing healthcare disparities in cancer care. [Montefiore Medical Center] Press Release
Nintedanib Receives Positive CHMP Opinion for Second-Line Treatment of Patients with Adenocarcinoma of the Lung
Boehringer Ingelheim announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion for the approval of nintedanib in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer of adenocarcinoma tumor histology after first-line chemotherapy. [Boehringer Ingelheim GmbH] Press Release
Recruit Top Talent: Reach more than 50,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!